<p>Enliven Therapeutics（纳斯达克代码：ELVN - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场开盘前发布其 2026 年第一季度财报。分析师预计 Enliven Therapeutics 本季度每股收益为（$0.44）。感兴趣的人员可以查看公司即将发布的 2026 年第一季度财报的信息，了解定于 2026 年 5 月 11 日星期一东部时间下午 4:00 的电话会议的最新细节。</p>
<p>获取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
<p>Enliven Therapeutics（纳斯达克代码：ELVN - 获取免费报告）最近一次公布财报是在 3 月 3 日星期二。公司报告本季度每股收益为（$0.48），低于分析师一致预期的（$0.42），差距为（$0.06）。分析师平均预计 Enliven Therapeutics 在当前财年每股收益为-$2，在下一个财年每股收益也为-$2。</p>
<h2>Enliven Therapeutics 股票下跌 0.1%</h2>
<p>ELVN 的股票在星期三开盘时为$41.58。该公司的市值为 25.3 亿美元，市盈率为-22.35，贝塔值为 0.32。该公司的 50 日移动平均为$36.54，200 日移动平均为$27.06。Enliven Therapeutics 的 12 个月低点为$14.78，12 个月高点为$48.53。</p>
<h2>分析师评级变动</h2>
<p>几位股票研究分析师最近对该股票发表了看法。HC Wainwright 在 3 月 26 日星期四的研究报告中将 Enliven Therapeutics 的目标股价从$48.00 上调至$56.00，并给予该公司 “买入” 评级。Wall Street Zen 在周日的研究报告中将 Enliven Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 4 月 20 日星期一的研究报告中重新发布了对 Enliven Therapeutics 的 “卖出（d-）” 评级。最后，瑞穗证券在 3 月 25 日星期三的研究报告中将 Enliven Therapeutics 的目标股价从$41.00 上调至$45.00，并给予该公司 “跑赢大盘” 评级。五位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价格为$43.40。</p>
<p><strong>查看我们关于 Enliven Therapeutics 的最新报告</strong></p>
<h2>内部人员买卖</h2>
<p>在相关消息中，董事 Richard A. Heyman 在 2 月 17 日星期二出售了 1,230 股公司的股票。该股票以平均价格$26.18 出售，总价值为$32,201.40。出售后，该董事在公司持有 22,647 股，价值约为$592,898.46。这笔交易代表其持股比例下降了 5.15%。该出售在提交给 SEC 的文件中披露，相关文件可通过 SEC 网站访问。此外，首席财务官 Benjamin Hohl 在 3 月 6 日星期五出售了 10,000 股公司的股票。该股票以平均价格$29.58 出售，总交易额为$295,800.00。出售完成后，首席财务官在公司持有 51,000 股，价值为$1,508,580。这代表其持股比例下降了 16.39%。该出售的 SEC 文件提供了更多信息。在上个季度，内部人员出售了价值$473,201 的 16,230 股公司股票。内部人员持有 25.90% 的股票。</p>
<h2>机构投资者对 Enliven Therapeutics 的看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该股票的持股。Commodore Capital LP 在第二季度将其在 Enliven Therapeutics 的持股增加了 0.4%。Commodore Capital LP 现在拥有 4,692,809 股公司股票，价值$94,138,000，在上个季度购买了额外的 17,809 股。Vestal Point Capital LP 在第四季度将其在 Enliven Therapeutics 的持股增加了 230.2%。Vestal Point Capital LP 现在拥有 3,830,000 股公司股票，价值$58,982,000，在上个季度额外收购了 2,670,000 股。Polar Capital Holdings Plc 在第三季度将其在 Enliven Therapeutics 的持股增加了 1.5%。Polar Capital Holdings Plc 现在拥有 3,095,007 股公司股票，价值$63,355,000，在上个季度额外收购了 44,713 股。先锋集团在第三季度将其在 Enliven Therapeutics 的持股增加了 5.9%。先锋集团现在拥有 2,553,014 股公司股票，价值$52,260,000，在上个季度额外收购了 142,378 股。最后，State Street Corp 在第四季度将其在 Enliven Therapeutics 的持股增加了 9.1%。State Street Corp 现在拥有 1,052,862 股公司股票，价值$16,214,000，在上个季度额外收购了 87,725 股。对冲基金和其他机构投资者持有公司 95.08% 的股票。</p>
<h2>Enliven Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Enliven Therapeutics 是一家临床阶段的生物技术公司，专注于开发小分子疗法，利用诱导接近机制选择性地靶向和降解癌症中致病蛋白。该公司利用其专有的诱导接近平台，设计分子胶和相关方式，以招募内源性细胞机制进行靶向蛋白降解，目标是治疗由所谓 “难以药物化” 的肿瘤因子驱动的恶性肿瘤。</p>
<p>该公司的管道包括多个早期阶段的项目，针对血液和实体肿瘤指示中的关键肿瘤驱动因子。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Enliven Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUVMVk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUVMVk4"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Enliven Therapeutics 吗？</h2>
<p>在考虑 Enliven Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enliven Therapeutics 并不在名单上。</p>
<p>虽然 Enliven Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ELVN

<p>Enliven Therapeutics（纳斯达克代码：ELVN）将于 5 月 13 日发布 2026 年第一季度财报，分析师预测每股亏损为 0.44 美元。该公司最近报告了上一季度每股亏损 0.48 美元，未能达到预期。当前股价为 41.58 美元，市值为 25.3 亿美元。分析师评级各异，五位分析师给予 “买入” 评级，一位给予 “卖出” 评级。内部交易活动包括首席财务官和一位董事的近期出售。机构投资者也已调整了在该公司的持股</p>

<p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Enliven Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.</p>
<div class="lb-trans"><p>Enliven Therapeutics（纳斯达克代码：ELVN - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场开盘前发布其 2026 年第一季度财报。分析师预计 Enliven Therapeutics 本季度每股收益为（$0.44）。感兴趣的人员可以查看公司即将发布的 2026 年第一季度财报的信息，了解定于 2026 年 5 月 11 日星期一东部时间下午 4:00 的电话会议的最新细节。</p>
</div><p>Get <strong>Enliven Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Enliven Therapeutics</strong> 的提醒：</p>
</div><p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Enliven Therapeutics（纳斯达克代码：ELVN - 获取免费报告）最近一次公布财报是在 3 月 3 日星期二。公司报告本季度每股收益为（$0.48），低于分析师一致预期的（$0.42），差距为（$0.06）。分析师平均预计 Enliven Therapeutics 在当前财年每股收益为-$2，在下一个财年每股收益也为-$2。</p>
</div><h2>Enliven Therapeutics Stock Down 0.1%</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 股票下跌 0.1%</h2>
</div><p>Shares of ELVN opened at $41.58 on Wednesday. The company has a market capitalization of $2.53 billion, a P/E ratio of -22.35 and a beta of 0.32. The firm has a 50 day moving average of $36.54 and a 200 day moving average of $27.06. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $48.53.</p>
<div class="lb-trans"><p>ELVN 的股票在星期三开盘时为$41.58。该公司的市值为 25.3 亿美元，市盈率为-22.35，贝塔值为 0.32。该公司的 50 日移动平均为$36.54，200 日移动平均为$27.06。Enliven Therapeutics 的 12 个月低点为$14.78，12 个月高点为$48.53。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities research analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 26th. Wall Street Zen downgraded shares of Enliven Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Mizuho raised their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an &#34;outperform&#34; rating in a research report on Wednesday, March 25th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $43.40.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了看法。HC Wainwright 在 3 月 26 日星期四的研究报告中将 Enliven Therapeutics 的目标股价从$48.00 上调至$56.00，并给予该公司 “买入” 评级。Wall Street Zen 在周日的研究报告中将 Enliven Therapeutics 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 4 月 20 日星期一的研究报告中重新发布了对 Enliven Therapeutics 的 “卖出（d-）” 评级。最后，瑞穗证券在 3 月 25 日星期三的研究报告中将 Enliven Therapeutics 的目标股价从$41.00 上调至$45.00，并给予该公司 “跑赢大盘” 评级。五位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，平均目标价格为$43.40。</p>
</div><p><strong>View Our Latest Report on Enliven Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Enliven Therapeutics 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In related news, Director Richard A. Heyman sold 1,230 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares in the company, valued at $1,508,580. This represents a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 16,230 shares of company stock worth $473,201. 25.90% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Richard A. Heyman 在 2 月 17 日星期二出售了 1,230 股公司的股票。该股票以平均价格$26.18 出售，总价值为$32,201.40。出售后，该董事在公司持有 22,647 股，价值约为$592,898.46。这笔交易代表其持股比例下降了 5.15%。该出售在提交给 SEC 的文件中披露，相关文件可通过 SEC 网站访问。此外，首席财务官 Benjamin Hohl 在 3 月 6 日星期五出售了 10,000 股公司的股票。该股票以平均价格$29.58 出售，总交易额为$295,800.00。出售完成后，首席财务官在公司持有 51,000 股，价值为$1,508,580。这代表其持股比例下降了 16.39%。该出售的 SEC 文件提供了更多信息。在上个季度，内部人员出售了价值$473,201 的 16,230 股公司股票。内部人员持有 25.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Enliven Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Enliven Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Commodore Capital LP boosted its holdings in Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock worth $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 1.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company's stock worth $63,355,000 after acquiring an additional 44,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock worth $52,260,000 after acquiring an additional 142,378 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company's stock worth $16,214,000 after acquiring an additional 87,725 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该股票的持股。Commodore Capital LP 在第二季度将其在 Enliven Therapeutics 的持股增加了 0.4%。Commodore Capital LP 现在拥有 4,692,809 股公司股票，价值$94,138,000，在上个季度购买了额外的 17,809 股。Vestal Point Capital LP 在第四季度将其在 Enliven Therapeutics 的持股增加了 230.2%。Vestal Point Capital LP 现在拥有 3,830,000 股公司股票，价值$58,982,000，在上个季度额外收购了 2,670,000 股。Polar Capital Holdings Plc 在第三季度将其在 Enliven Therapeutics 的持股增加了 1.5%。Polar Capital Holdings Plc 现在拥有 3,095,007 股公司股票，价值$63,355,000，在上个季度额外收购了 44,713 股。先锋集团在第三季度将其在 Enliven Therapeutics 的持股增加了 5.9%。先锋集团现在拥有 2,553,014 股公司股票，价值$52,260,000，在上个季度额外收购了 142,378 股。最后，State Street Corp 在第四季度将其在 Enliven Therapeutics 的持股增加了 9.1%。State Street Corp 现在拥有 1,052,862 股公司股票，价值$16,214,000，在上个季度额外收购了 87,725 股。对冲基金和其他机构投资者持有公司 95.08% 的股票。</p>
</div><h2>Enliven Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.</p>
<div class="lb-trans"><p>Enliven Therapeutics 是一家临床阶段的生物技术公司，专注于开发小分子疗法，利用诱导接近机制选择性地靶向和降解癌症中致病蛋白。该公司利用其专有的诱导接近平台，设计分子胶和相关方式，以招募内源性细胞机制进行靶向蛋白降解，目标是治疗由所谓 “难以药物化” 的肿瘤因子驱动的恶性肿瘤。</p>
</div><p>The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.</p>
<div class="lb-trans"><p>该公司的管道包括多个早期阶段的项目，针对血液和实体肿瘤指示中的关键肿瘤驱动因子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Enliven Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Enliven Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxWTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ELVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Enliven Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Enliven Therapeutics 吗？</h2>
</div><p>Before you consider Enliven Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Enliven Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enliven Therapeutics 并不在名单上。</p>
</div><p>While Enliven Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enliven Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Enliven Therapeutics (ELVN) 预计将在周三发布财报